You are here: Industry Insights > Biocytogen

News List

Biocytogen Completes a New Round of Financing Totaling Tens of Millions of Dollars prnasia
June 23, 2021
Biocytogen today announced the successful completion of a new round of financing totaling tens of millions of dollars. The financing was jointly completed by Lake Bleu Capital, CPE, Octagon Capital and OrbiMed.
Eucure Biopharma Announces Breakthrough Phase I Results for Anti-CTLA-4 Therapy americanpharmaceuticalreview
March 26, 2021
Eucure Biopharma, a subsidiary of Biocytogen, announced its anti-CTLA-4 antibody (YH001), in combination with Junshi Biosciences' anti-PD-1 monoclonal antibody, Toripalimab Injection (TUOYI®), has demonstrated encouraging anti-tumor activity in a ...
Eucure Biopharma Announces Breakthrough Phase I Results for Anti-CTLA-4 Therapy in Combination with Junshi Biosciences' Anti-PD-1 prnasia
March 23, 2021
Eucure Biopharma, a subsidiary of Biocytogen focused on developing proprietary immuno-oncology antibodies, announced that its anti-CTLA-4 antibody (YH001), in combination with Junshi Biosciences' anti-PD-1 monoclonal antibody, Toripalimab Injection ...
Eucure Biopharma Announces Encouraging Antitumor Activity of Its anti-CD40 Antibody in PD-1 Refractory Ocular Melanoma when Combined with Junshi Biosciences' Toripalimab prnasia
February 04, 2021
Eucure Biopharma, a biopharmaceutical company dedicated to developing immuno-oncology antibody drugs, announced that its investigational anti-CD40 antibody drug (YH003), when combined with Junshi Biosciences' anti-PD-1 antibody Toripalimab (TUOYI®) ...
Biocytogen Subsidiary Eucure Biopharma Reports First Patient Enrolled in anti-CTLA4 Phase I Trial in China prnasia
January 27, 2021
Eucure Biopharma announced the first patient enrollment for a Phase I clinical trial in China to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of its anti-CTLA4 monoclonal antibody (YH001) in patients with solid tumors.
Strategic Cooperation between GeneQuantum Healthcare and Biocytogen on Development of Antitumor Bioconjugates pharmafocusasia
November 05, 2018
GeneQuantum Healthcare and Biocytogen reached a Strategic Cooperation Agreement focusing on the development of next generation bioconjugates...